Author:
Amatu Alessio,Schirripa Marta,Tosi Federica,Lonardi Sara,Bencardino Katia,Bonazzina Erica,Palmeri Laura,Patanè Damiano Alfio,Pizzutilo Elio Gregory,Mussolin Benedetta,Bergamo Francesca,Alberti Giulia,Intini Rossana,Procaccio Letizia,Arese Marco,Marsoni Silvia,Nichelatti Michele,Zagonel Vittorina,Siena Salvatore,Bardelli Alberto,Loupakis Fotios,Di Nicolantonio Federica,Sartore-Bianchi Andrea,Barault Ludovic
Funder
Associazione Italiana per la Ricerca sul Cancro
Università degli Studi di Torino
Ministero della Salute
Horizon 2020 Framework Programme
Innovative Medicines Initiative
Regione del Veneto
Reference37 articles.
1. Cancer statistics, 2018;Siegel;CA Cancer J Clin.,2018
2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol.,2014
3. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer;Loupakis;N Engl J Med.,2014
4. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model;Abou-Elkacem;Mol Cancer Ther.,2013
5. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer;Schmieder;Int J Cancer.,2014
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献